ECSP045148A - Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil]acetamida, y su preparación y uso contra el cancer - Google Patents
Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil]acetamida, y su preparación y uso contra el cancerInfo
- Publication number
- ECSP045148A ECSP045148A EC2004005148A ECSP045148A ECSP045148A EC SP045148 A ECSP045148 A EC SP045148A EC 2004005148 A EC2004005148 A EC 2004005148A EC SP045148 A ECSP045148 A EC SP045148A EC SP045148 A ECSP045148 A EC SP045148A
- Authority
- EC
- Ecuador
- Prior art keywords
- methyl
- acetamide
- methylpiridin
- iloxi
- metoxi
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000002690 malonic acid derivatives Chemical class 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a las sales succinato y malonato de E-2-metoxi-N-(3-{4-[3-metil-4-(6-metil-piridin-3-iloxi) fenilamino]quinazolina-6-il}alil)-acetamida de la siguiente fórmula I. Más particularmente, la presente invención se refiere a las sales sesquisuccinato y dimalonato de fórmula I. La invención se refiere también a composiciones farmacéuticas que contienen las sales succinato y malonato de fórmula I. La invención se refiere además a procedimientos de tratamiento de enfermedades hiperproliferativas tales como los cánceres en mamíferos, especialmente en seres humanos, mediante la administración de las sales anteriores y a procedimientos de preparación de las sales anteriores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34088501P | 2001-12-12 | 2001-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045148A true ECSP045148A (es) | 2004-07-23 |
Family
ID=23335337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005148A ECSP045148A (es) | 2001-12-12 | 2004-06-11 | Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil]acetamida, y su preparación y uso contra el cancer |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6844349B2 (es) |
| EP (1) | EP1456199A1 (es) |
| JP (1) | JP4202926B2 (es) |
| KR (1) | KR20040065259A (es) |
| CN (1) | CN1608062A (es) |
| AP (1) | AP2004003059A0 (es) |
| AR (1) | AR037772A1 (es) |
| AU (1) | AU2002366581A1 (es) |
| BR (1) | BR0214876A (es) |
| CA (1) | CA2469889A1 (es) |
| DO (1) | DOP2002000544A (es) |
| EA (1) | EA007412B1 (es) |
| EC (1) | ECSP045148A (es) |
| GE (1) | GEP20063872B (es) |
| GT (1) | GT200200272A (es) |
| HR (1) | HRP20040530A2 (es) |
| HU (1) | HUP0402662A2 (es) |
| IL (1) | IL161915A0 (es) |
| IS (1) | IS7227A (es) |
| MA (1) | MA27095A1 (es) |
| MX (1) | MXPA04005678A (es) |
| NO (1) | NO20042925L (es) |
| NZ (1) | NZ532436A (es) |
| OA (1) | OA12735A (es) |
| PA (1) | PA8561401A1 (es) |
| PE (1) | PE20030716A1 (es) |
| PL (1) | PL370858A1 (es) |
| RS (1) | RS46404A (es) |
| TN (1) | TNSN04112A1 (es) |
| TW (1) | TW200301103A (es) |
| UA (1) | UA75482C2 (es) |
| UY (1) | UY27572A1 (es) |
| WO (1) | WO2003050108A1 (es) |
| ZA (1) | ZA200402995B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1602195A (zh) * | 2001-12-12 | 2005-03-30 | 辉瑞产品公司 | 用于治疗异常细胞生长的喹唑啉衍生物 |
| WO2004006846A2 (en) | 2002-07-15 | 2004-01-22 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
| MXPA05006335A (es) * | 2002-12-18 | 2005-08-26 | Pfizer Prod Inc | Derivados biciclicos para el tratamiento del crecimiento celular anormal. |
| PL377533A1 (pl) * | 2002-12-19 | 2006-02-06 | Pfizer Products Inc. | Kompleksy E-2-metoksy-N-(3-{4-[3-metylo-4-(6-metylopirydyn-3-yloksy)-fenyloamino]-chinazolin-6-ylo}-allilo)-acetamidu, sposób ich wytwarzania i zastosowanie |
| CA2523083C (en) | 2003-04-25 | 2014-07-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| WO2005016347A1 (en) * | 2003-08-18 | 2005-02-24 | Pfizer Products Inc. | Dosing schedule for erbb2 anticancer agents |
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| BRPI0415836A (pt) * | 2003-10-27 | 2007-01-02 | Merck & Co Inc | composto, métodos para a modulação da atividade de receptor de quimocina em um mamìfero, e para o tratamento, a melhoria, o controle ou a redução do risco de uma doença ou distúrbio inflamatório e imunorregulatório, e de artrite reumatóide, composição farmacêutica |
| US20050192298A1 (en) * | 2004-02-27 | 2005-09-01 | Pfizer Inc | Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide |
| WO2005121124A1 (en) * | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Complexes of e-2-methoxy-n-(3-{4-[3-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and methods of preparing same |
| JP2008508291A (ja) | 2004-07-27 | 2008-03-21 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ｈｉｖ剤としてのヌクレオシドホスホネート結合体 |
| EP1896451A2 (en) * | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Bicyclic derivatives for the treatment of abnormal cell growth |
| CA2610661A1 (en) * | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| ES2377467T3 (es) * | 2006-05-16 | 2012-03-27 | Gilead Sciences, Inc. | Procedimiento y composiciones para tratar enfermedades hematológicas malignas |
| JPWO2008072634A1 (ja) | 2006-12-12 | 2010-04-02 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| NZ577716A (en) * | 2006-12-21 | 2012-10-26 | Pfizer Prod Inc | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
| NZ580868A (en) * | 2007-04-10 | 2011-07-29 | Myriad Pharmaceuticals Inc | Dosages and methods for the treatment of cancer |
| EP2253633A4 (en) | 2008-03-12 | 2012-02-29 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| EP2307435B1 (en) | 2008-07-08 | 2012-06-13 | Gilead Sciences, Inc. | Salts of hiv inhibitor compounds |
| KR101733773B1 (ko) | 2009-01-16 | 2017-05-10 | 엑셀리시스, 인코포레이티드 | Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US9265739B2 (en) | 2010-06-02 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to HER2/neu receptor complex |
| WO2011153049A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| JP6914860B2 (ja) | 2015-07-01 | 2021-08-04 | カリフォルニア インスティチュート オブ テクノロジー | カチオン性粘液酸ポリマー系デリバリーシステム |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| EP3661937B1 (en) | 2017-08-01 | 2021-07-28 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections |
| US20190381188A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same |
| KR20230035050A (ko) * | 2020-07-06 | 2023-03-10 | 깃세이 야쿠힌 고교 가부시키가이샤 | 옥타히드로티에노퀴놀린 화합물의 숙신산염 및 그 결정 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884418B1 (en) * | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EP0912559B1 (en) * | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| BR0111548A (pt) * | 2000-06-22 | 2003-05-06 | Pfizer Prod Inc | Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal |
-
2002
- 2002-11-11 HU HU0402662A patent/HUP0402662A2/hu unknown
- 2002-11-11 JP JP2003551132A patent/JP4202926B2/ja not_active Expired - Fee Related
- 2002-11-11 MX MXPA04005678A patent/MXPA04005678A/es active IP Right Grant
- 2002-11-11 KR KR10-2004-7009073A patent/KR20040065259A/ko not_active Ceased
- 2002-11-11 EA EA200400674A patent/EA007412B1/ru not_active IP Right Cessation
- 2002-11-11 IL IL16191502A patent/IL161915A0/xx unknown
- 2002-11-11 CA CA002469889A patent/CA2469889A1/en not_active Abandoned
- 2002-11-11 AP APAP/P/2004/003059A patent/AP2004003059A0/en unknown
- 2002-11-11 NZ NZ532436A patent/NZ532436A/en unknown
- 2002-11-11 BR BR0214876-5A patent/BR0214876A/pt not_active IP Right Cessation
- 2002-11-11 GE GE5562A patent/GEP20063872B/en unknown
- 2002-11-11 AU AU2002366581A patent/AU2002366581A1/en not_active Abandoned
- 2002-11-11 OA OA1200400161A patent/OA12735A/en unknown
- 2002-11-11 EP EP02804543A patent/EP1456199A1/en not_active Withdrawn
- 2002-11-11 WO PCT/IB2002/004708 patent/WO2003050108A1/en not_active Ceased
- 2002-11-11 UA UA20040604566A patent/UA75482C2/uk unknown
- 2002-11-11 CN CNA028248554A patent/CN1608062A/zh active Pending
- 2002-11-11 HR HR20040530A patent/HRP20040530A2/hr not_active Application Discontinuation
- 2002-11-11 RS YU46404A patent/RS46404A/sr unknown
- 2002-11-11 PL PL02370858A patent/PL370858A1/xx not_active Application Discontinuation
- 2002-12-06 TW TW091135465A patent/TW200301103A/zh unknown
- 2002-12-09 UY UY27572A patent/UY27572A1/es not_active Application Discontinuation
- 2002-12-10 PE PE2002001185A patent/PE20030716A1/es not_active Application Discontinuation
- 2002-12-10 US US10/315,862 patent/US6844349B2/en not_active Expired - Fee Related
- 2002-12-10 DO DO2002000544A patent/DOP2002000544A/es unknown
- 2002-12-10 AR ARP020104779A patent/AR037772A1/es unknown
- 2002-12-12 GT GT200200272A patent/GT200200272A/es unknown
- 2002-12-12 PA PA20028561401A patent/PA8561401A1/es unknown
-
2004
- 2004-04-19 IS IS7227A patent/IS7227A/is unknown
- 2004-04-20 ZA ZA200402995A patent/ZA200402995B/en unknown
- 2004-06-08 MA MA27730A patent/MA27095A1/fr unknown
- 2004-06-11 EC EC2004005148A patent/ECSP045148A/es unknown
- 2004-06-11 TN TNP2004000112A patent/TNSN04112A1/fr unknown
- 2004-07-09 NO NO20042925A patent/NO20042925L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045148A (es) | Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil]acetamida, y su preparación y uso contra el cancer | |
| UY27740A1 (es) | Nuevos compuestos | |
| ECSP056019A (es) | 2,4-di(fenilamino)pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmune | |
| BR0113838A (pt) | Derivados de n-fenil-2-pirimidina-amina | |
| PA8551001A1 (es) | Nuevos compuestos | |
| ECSP088283A (es) | Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
| MXPA05012573A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa. | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| UY27714A1 (es) | 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos. | |
| CO5271715A1 (es) | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa | |
| AR022860A1 (es) | Derivados de camptotecina que poseen actividad antitumoral | |
| UY27592A1 (es) | Nuevo uso | |
| BRPI0410760A (pt) | compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| BRPI0514750A (pt) | derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase | |
| PA8604201A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| SE0100569D0 (sv) | New compounds | |
| UY27593A1 (es) | Nuevos compuestos | |
| UY28536A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
| BR0314195A (pt) | Derivados de piridina substituìda como agentes antitumorais | |
| PA8603001A1 (es) | Compuestos utiles para el tratamiento de enfermedades | |
| BR0209645A (pt) | Oxazolo- e furopirimidinas e seu uso como medicamentos | |
| BRPI0415203A (pt) | pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios | |
| UY28356A1 (es) | Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos | |
| AR025046A1 (es) | Inhibidores il-5 no esteroidales, procedimientos e intermediarios para su preparacion y composiciones farmaceuticas que comprenden dichos inhibidores |